E.E. Geduld’s Celldex Therapeutics CLDX Stock Holding History

E.E. Geduld’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-667	Closed	-$252K	–	218
2015 Q2	$252K	Sell	667 -412	-38%	-$164K	0.16%	148
2015 Q1	$451K	Buy	1,079 +412	+62%	+$147K	0.3%	80
2014 Q4	$183K	Buy	+667	New	+$166K	0.1%	145

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

E.E. Geduld's CLDX Position: Q3 2015 in Review

E.E. Geduld sold out of Celldex Therapeutics (CLDX) in Q3 2015, closing a stake of 667 shares — an estimated $252K sold.

E.E. Geduld first reported a position in CLDX in Q4 2014 and held it in 3 quarters. The position peaked at $451K in Q1 2015. 162 funds tracked by Wall St. Rank hold CLDX as of Q3 2015.

E.E. Geduld reported no remaining Celldex Therapeutics position as of Q3 2015 after selling out during the quarter.
E.E. Geduld sold 667 Celldex Therapeutics shares in Q3 2015, an estimated $252K.
E.E. Geduld first reported a position in Celldex Therapeutics in Q4 2014 and held it in 3 quarters.
E.E. Geduld's Celldex Therapeutics position peaked at $451K in Q1 2015.
162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2015.

Based on E.E. Geduld's 13F filing for Q3 2015, filed 6 Nov 2015.